The Appellate Division in Seigelstein v. Shrewsbury Motors, Inc., reiterated the importance of the “lodestar” principal regarding attorneys fees originally set forth in Rendine v. Pantzer, whereby the starting point in calculating such fees is the number of hours reasonably expended on the litigation multiplied by a reasonable hourly rate.
The 3rd Circuit affirmed granting class certification to a group of who purchased Suboxone from its manufacturer in In re Suboxone Antitrust Litigation. The class alleged that the manufacturer engaged in unfair trade practice to drive prescribers away from Suboxone tablets and toward under-the-tongue films in order to drive market share away from generic tablet … Read more
This class action proceeded to trial and the jury agreed with plaintiffs that defendant breached express and implied warranties by selling plaintiffs cars with defective break pads. The jury awarded $750 to each plaintiff. The trial court granted defendant’s post trial motion regarding damages only. The trial court left the verdict intact to liability. But … Read more
In this antitrust class action, the plaintiffs, who were purchasers of eggs, claim the defendant egg producers conspired to inflate prices using three methods to do so. Before the District Court, the plaintiffs argued that all three of those methods were part of a single overarching conspiracy that was anti-competitive per se and therefore unlawful under … Read more
In this securities class action suit, a class of shareholders sued M&T Bank as a result of its intended merger with Hudson Bank. The two banks issued a joint proxy to their shareholders pursuant to the Securities Exchange Act and related regulations in order to apprise their respective shareholders of the risks and rewards of … Read more
#ClassAction #ClassCertification 04/22/2020- This case was the latest in the years-long antitrust battle over whether GlaxoSmithKline (“GSK”) and Teva Pharmaceuticals (“Teva”) violated the antitrust laws through their settlement agreement to end an unrelated patent dispute over GSK’s brand drug Lamictal and Teva’s generic form lamotrigine. After GSK and Teva settled patent litigation, plaintiffs—companies that directly purchased … Read more